Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 81M | 0% |
| Net Income | -71M | 0.3% |
| EBITDA | -69M | 0.3% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 1.11B | 4% |
| Total Liabilities | 83M | 15.7% |
| Total Equity | 1.03B | 5.4% |
| Shares Outstanding | 82M | 3.9% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -48M | 28.7% |
| Cash from investing | 79M | 116.5% |
| Cash from financing | 3.4M | 99.1% |
EPS
Financial Highlights for Akero Therapeutics in Q2 '25
Operating Expenses for this period were 81M, showing a -0% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -71M, showing a 0.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -69M, showing a 0.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
